Literature DB >> 1940487

The incidence of narcotic-induced emesis.

E Campora, L Merlini, M Pace, M Bruzzone, M Luzzani, A Gottlieb, R Rosso.   

Abstract

Epidemiologic studies of the incidence of emesis induced by narcotic analgesics are lacking. The histories of 260 cancer patients receiving oral narcotic analgesics prescribed at the Pain Clinic of our Institute from December 1988 to December 1989 were reviewed. Of the 260 patients, 120 were women, median age 61 (range 30-90) yr and 140 were men, median age 62 (range 30-82) yr. Nausea and vomiting associated with assumption of the various narcotics were buprenorphine 8.3% and 22.7%, morphine 18.3% and 28%, codeine 16.2% and 29.7%, and oxycodone 10% and 40%, respectively. Since the use of narcotic analgesics can effectively relieve pain and improve quality of life in cancer patients, it is important to be aware of the incidence of narcotic-induced emesis in order to use appropriate prophylactic antiemetic therapy.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1940487     DOI: 10.1016/0885-3924(91)90041-2

Source DB:  PubMed          Journal:  J Pain Symptom Manage        ISSN: 0885-3924            Impact factor:   3.612


  20 in total

Review 1.  Responsible prescribing of opioids for the management of chronic pain.

Authors:  Bruce Nicholson
Journal:  Drugs       Date:  2003       Impact factor: 9.546

2.  Nausea and vomiting in palliative care.

Authors:  Charlotte Leach
Journal:  Clin Med (Lond)       Date:  2019-07       Impact factor: 2.659

3.  Acute oxycodone induces the pro-emetic pica response in rats.

Authors:  Vinita R Batra; Lisa M Schrott
Journal:  J Pharmacol Exp Ther       Date:  2011-08-29       Impact factor: 4.030

Review 4.  2016 Updated MASCC/ESMO consensus recommendations: Management of nausea and vomiting in advanced cancer.

Authors:  Declan Walsh; Mellar Davis; Carla Ripamonti; Eduardo Bruera; Andrew Davies; Alex Molassiotis
Journal:  Support Care Cancer       Date:  2016-08-17       Impact factor: 3.603

Review 5.  Buprenorphine in cancer pain.

Authors:  Mellar P Davis
Journal:  Support Care Cancer       Date:  2005-07-12       Impact factor: 3.603

6.  Evaluation of buprenorphine in a postoperative pain model in rats.

Authors:  Leslie I Curtin; Julie A Grakowsky; Mauricio Suarez; Alexis C Thompson; Jean M DiPirro; Lisa B E Martin; Mark B Kristal
Journal:  Comp Med       Date:  2009-02       Impact factor: 0.982

Review 7.  Nausea and vomiting in people with cancer and other chronic diseases.

Authors:  Paul W Keeley
Journal:  BMJ Clin Evid       Date:  2009-01-13

Review 8.  [Treatment of nausea and vomiting with prokinetics and neuroleptics in palliative care patients : a review].

Authors:  G Benze; B Alt-Epping; A Geyer; F Nauck
Journal:  Schmerz       Date:  2012-09       Impact factor: 1.107

9.  Less nausea, emesis, and constipation comparing hydromorphone and morphine? A prospective open-labeled investigation on cancer pain.

Authors:  S Wirz; H C Wartenberg; J Nadstawek
Journal:  Support Care Cancer       Date:  2007-12-20       Impact factor: 3.603

10.  Use of a prophylactic antiemetic with morphine in acute pain: randomised controlled trial.

Authors:  M Bradshaw; A Sen
Journal:  Emerg Med J       Date:  2006-03       Impact factor: 2.740

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.